Literature DB >> 14962587

Phase transformation considerations during process development and manufacture of solid oral dosage forms.

Geoff G Z Zhang1, Devalina Law, Eric A Schmitt, Yihong Qiu.   

Abstract

The quality and performance of a solid oral dosage form depends on the choice of the solid phase, the formulation design, and the manufacturing process. The potential for process-induced solid phase transformations must be evaluated during design and development of formulations and manufacturing processes. This article briefly reviews the basic principles of polymorphism, defines the classes of phase transformation and the underlying transformation mechanisms, and discusses respective kinetic factors. The potential phase transformations associated with common unit operations employed in manufacturing solid oral dosage forms are highlighted. Specific examples are given to illustrate the importance of solid phases, and process-induced phase transitions in formulation and process development.

Mesh:

Substances:

Year:  2004        PMID: 14962587     DOI: 10.1016/j.addr.2003.10.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  30 in total

1.  Quantitative measurement of indomethacin crystallinity in indomethacin-silica gel binary system using differential scanning calorimetry and X-ray powder diffractometry.

Authors:  Xiaohong Pan; Thomas Julian; Larry Augsburger
Journal:  AAPS PharmSciTech       Date:  2006-02-10       Impact factor: 3.246

2.  Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: a technical note.

Authors:  Vimon Tantishaiyakul; Pattakarn Permkam; Krit Suknuntha
Journal:  AAPS PharmSciTech       Date:  2008-01-15       Impact factor: 3.246

3.  Overcoming poor tabletability of pharmaceutical crystals by surface modification.

Authors:  Limin Shi; Changquan Calvin Sun
Journal:  Pharm Res       Date:  2011-06-28       Impact factor: 4.200

4.  Exploring the solid-form landscape of pharmaceutical hydrates: transformation pathways of the sodium naproxen anhydrate-hydrate system.

Authors:  Dhara Raijada; Andrew D Bond; Flemming H Larsen; Claus Cornett; Haiyan Qu; Jukka Rantanen
Journal:  Pharm Res       Date:  2012-09-21       Impact factor: 4.200

5.  A kinetic study of the polymorphic transformation of nimodipine and indomethacin during high shear granulation.

Authors:  Zhen Guo; Mingxin Ma; Tianyi Wang; Di Chang; Tongying Jiang; Siling Wang
Journal:  AAPS PharmSciTech       Date:  2011-05-07       Impact factor: 3.246

6.  Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation.

Authors:  Sari Airaksinen; Milja Karjalainen; Niina Kivikero; Sari Westermarck; Anna Shevchenko; Jukka Rantanen; Jouko Yliruusi
Journal:  AAPS PharmSciTech       Date:  2005-10-06       Impact factor: 3.246

7.  Cocrystal Construction Between Rosuvastatin Calcium and L-asparagine with Enhanced Solubility and Dissolution Rate.

Authors:  Venkata Deepthi Vemuri; Srinivas Lankalapalli
Journal:  Turk J Pharm Sci       Date:  2021-12-31

Review 8.  An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control.

Authors:  Shan-Yang Lin
Journal:  Pharm Res       Date:  2014-03-01       Impact factor: 4.200

9.  Rapid insight into heating-induced phase transformations in the solid state of the calcium salt of atorvastatin using multivariate data analysis.

Authors:  Niels Peter Aae Christensen; Bernard Van Eerdenbrugh; Kaho Kwok; Lynne S Taylor; Andrew D Bond; Thomas Rades; Jukka Rantanen; Claus Cornett
Journal:  Pharm Res       Date:  2012-11-10       Impact factor: 4.200

10.  Computational and Experimental Characterization of Five Crystal Forms of Thymine: Packing Polymorphism, Polytypism/Disorder and Stoichiometric 0.8-Hydrate.

Authors:  Doris E Braun; Thomas Gelbrich; Klaus Wurst; Ulrich J Griesser
Journal:  Cryst Growth Des       Date:  2016-06-01       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.